Advancing CAR T-cell therapy in hematologic malignancies highlights innovations in immunotherapy and cancer treatment.
Read More
Explore how a U.S. biotech partnered with a CRO to manage a Phase I oncology trial for advanced epithelial tumors.
Explore how TFS HealthScience navigated the complexities of DMD gene therapy studies, ensuring successful site selection and patient recruitment.
Discover TFS’s role in achieving early-phase oncology success for a European biotech targeting advanced solid tumors.
Discover the strategic solutions TFS implemented to support a biotech company’s adoptive cell therapy study during the COVID-19 pandemic. Learn about overcoming regulatory and logistical hurdles in this compelling case study. Download now for exclusive insights.
Delve into how TFS leveraged vast US real-world data to secure EMA approval for an extended-release CNS drug, bypassing traditional costly trials.
Discover how TFS harnessed the power of Real-World Evidence (RWE) to transform a high-stakes clinical trial into a groundbreaking respiratory treatment in newborns.
Uncover the blueprint for achieving excellence in an FSP collaboration, where agility, reliability, and effectiveness drive unprecedented success.
Discover how TFS revolutionized home care nursing amidst the COVID-19 crisis, training and deploying resources under tight timelines to unveil significant COVID-19 insights.
Discover how TFS’ expertise and experience delivered tailored solutions in a Phase IIIb study on Plaque Psoriasis in Adolescents.
Learn how TFS successfully navigated a complex Phase I study aimed at evaluating a novel therapy with the potential to strengthen existing antibiotic treatments for MTB.
Discover the remarkable story of how TFS navigated the complexities of setting up a post-marketing Pharmacovigilance (PV) system.
Discover the remarkable story of how TFS HealthScience managed to rescue a critical Phase III Onychomycosis study from failure.
When a client asked for our help to run their Phase IIb Type 1 diabetes study, we knew our extensive diabetes expertise and experience in the proposed countries of Sweden, Spain, and the Czech Republic would be an asset.
Patient Recruitment of an international Phase III study in Prurigo Nodularis successfuly enrolled 6 weeks ahead of schedule.